Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Interventional Cardiac Electrophysiology
- Vol. 60 (1), 147-154
- https://doi.org/10.1007/s10840-020-00718-w
Abstract
Purpose Cerebral thromboembolic events are well-known complications of pulmonary vein isolation (PVI) and can manifest as stroke or silent cerebral embolic lesions. The aim of this study was to compare the incidence of cerebral embolic lesions (including silent cerebral embolism and stroke) after AF ablation in patients on vitamin K antagonists versus patients on non-vitamin K-dependent oral anticoagulants, and to identify corresponding clinical and procedural risk factors. Methods A total of 421 patients undergoing PVI were prospectively included into the study. Of these, 43.7% were on VKA and 56.3% on NOAC treatment (dabigatran, rivaroxaban, apixaban, and edoxaban). In the NOAC group, 38% of patients had an interruption of anticoagulation for 24–36 h. All patients underwent pre- and postprocedural cerebral magnetic resonance imaging. Results Periprocedural cerebral lesions occurred in 13.1% overall. Of these, three (0.7%) resulted in symptomatic cerebrovascular accidents and 52 (12.4%) in silent cerebral embolic lesions. Incidence of cerebral lesions was significantly higher in patients on NOAC compared with VKA (16% vs. 9.2%, respectively, p = 0.04), and in patients who had intraprocedural cardioversions compared with no cardivoersions (19.5% vs. 10.4%, respectively, p = 0.03). In multivariate analysis, both parameters were found to be independent risk factors for cerebral embolism. No significant difference between interrupted and uninterrupted NOAC administration could be detected. Conclusions In patients undergoing AF ablation, we identified the use of NOAC and intraprocedural cardioversion as independent risk factors for the occurrence of periprocedural cerebral embolic lesions.Keywords
This publication has 21 references indexed in Scilit:
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace, 2016
- Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta‐Analysis and Meta‐RegressionJournal of Cardiovascular Electrophysiology, 2016
- Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation – Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging –Circulation Journal, 2016
- Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter studyHeart Rhythm, 2015
- Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillationEuropean Heart Journal, 2015
- Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literatureEP Europace, 2013
- Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulationEP Europace, 2012
- Impact of Ablation Catheter Irrigation Design on Silent Cerebral Embolism After Radiofrequency Catheter Ablation of Atrial Fibrillation: Results from a Pilot StudyJournal of Cardiovascular Electrophysiology, 2012
- Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatmentEP Europace, 2011
- Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?Circulation, 2010